BY JOHN CARREYROU AND TOM MCGINTY
Surgeons who conducted clinical trials to test a Medtronic Inc. bone-growth protein widely used in spine surgery didn't report serious complications that arose in those trials in their research papers, a new study says.
Over the past decade, 15 of those surgeons have collectively received at least $62 million from the medical-device giant for unrelated work, according to a Wall Street Journal analysis of Medtronic documents and of recent disclosures made on the company's website.
Last week, the Senate Finance Committee began investigating whether Medtronic's large payments to the surgeons played a role in the fact they didn't report the ...
Email
Printer Friendly
Order Reprints
Most Recommended
“Our problem is the size of the...;”
“Actually, Obama doesn't really...;”
“Exactly right. So much talk...;”
“This class warfare stuff is just...;”
“Growth cures all revenue...;”